tetano
Editor, Senior Moderator
Eur J Pediatr
. 2023 Sep 13.
doi: 10.1007/s00431-023-05184-w. Online ahead of print. Susceptibility of SARS-CoV2 infection in children
Nicola Cotugno[SUP] 1 2 [/SUP], Donato Amodio[SUP] 1 2 [/SUP], Danilo Buonsenso[SUP] 3 4 [/SUP], Paolo Palma[SUP] 5 6 [/SUP]
Affiliations
Coronavirus disease 2019 in children presents with distinct phenotype in comparison to adults. Overall, the pediatric infection with a generally milder clinical course of the acute infection compared to adults still faces several unknown aspects. Specifically, the presence of a wide range of inflammatory manifestations, including multisystem inflammatory syndrome in children (MIS-C), myocarditis, and long COVID in the period after infection suggests a particular susceptibility of some children upon severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Albeit peculiar complications such as long covid are less frequent in children compared to adults, research on the relationship between inflammatory syndromes and SARS-CoV-2 is rapidly evolving. Conclusions: new studies and findings continue to emerge, providing further insights into the underlying mechanisms and potential therapeutic strategies. In the present work, we revised current knowledge of the main factors accounting for such variability upon SARS-CoV-2 infection over the pediatric age group. What is Known: • COVID19 in children overall showed a milder course compared to adults during the acute phase of the infection. • Children showed to be susceptible to a wide range of post infectious complications including multisystem inflammatory syndrome in children (MIS-C), myocarditis, neuroinflammation, and long COVID. What is New: • Mechanisms underlying susceptibility to a severe course of the infection were recently shown to pertain to the host. • A specific combination of HLA was recently shown to be associated to higher susceptibility to MIS-C in children.
Keywords: COVID-19 genetic susceptibility; COVID-19 vaccines; Long-COVID; MIS-C; Pediatric COVID-19.
. 2023 Sep 13.
doi: 10.1007/s00431-023-05184-w. Online ahead of print. Susceptibility of SARS-CoV2 infection in children
Nicola Cotugno[SUP] 1 2 [/SUP], Donato Amodio[SUP] 1 2 [/SUP], Danilo Buonsenso[SUP] 3 4 [/SUP], Paolo Palma[SUP] 5 6 [/SUP]
Affiliations
- PMID: 37702769
- DOI: 10.1007/s00431-023-05184-w
Coronavirus disease 2019 in children presents with distinct phenotype in comparison to adults. Overall, the pediatric infection with a generally milder clinical course of the acute infection compared to adults still faces several unknown aspects. Specifically, the presence of a wide range of inflammatory manifestations, including multisystem inflammatory syndrome in children (MIS-C), myocarditis, and long COVID in the period after infection suggests a particular susceptibility of some children upon severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Albeit peculiar complications such as long covid are less frequent in children compared to adults, research on the relationship between inflammatory syndromes and SARS-CoV-2 is rapidly evolving. Conclusions: new studies and findings continue to emerge, providing further insights into the underlying mechanisms and potential therapeutic strategies. In the present work, we revised current knowledge of the main factors accounting for such variability upon SARS-CoV-2 infection over the pediatric age group. What is Known: • COVID19 in children overall showed a milder course compared to adults during the acute phase of the infection. • Children showed to be susceptible to a wide range of post infectious complications including multisystem inflammatory syndrome in children (MIS-C), myocarditis, neuroinflammation, and long COVID. What is New: • Mechanisms underlying susceptibility to a severe course of the infection were recently shown to pertain to the host. • A specific combination of HLA was recently shown to be associated to higher susceptibility to MIS-C in children.
Keywords: COVID-19 genetic susceptibility; COVID-19 vaccines; Long-COVID; MIS-C; Pediatric COVID-19.